WW

WW just emerged from Chapter 11 on June 24, 2025, wiping out ~87.5% of the old share count (now 10.0M) and cutting long-term debt 67.5% to $466M. The company adopted fresh-start accounting, so the FY2025 balance sheet (equity $379M, cash $167M) is a re-baselined snapshot that is not comparable to the pre-emergence income statement — and no post-emergence revenue or profit trajectory is visible in the data. That comparability gap alone makes a confident valuation call impossible: at 0.2x sales the stock looks cheap, but you are pricing a business whose go-forward earning power is genuinely unknown.

What is knowable is bleak. Revenue has fallen every year from $1.41B (FY2019) to $786M (FY2024), including -11.6% in the latest full year, and the company posted a -$346M net loss with a -30.1% operating margin and -$16.8M of operating cash flow. The MD&A frames the pivot bluntly: WW is 'redefining weight management for the GLP-1 era,' now prescribing oral and injectable GLP-1s through affiliated clinics. But GLP-1 drugs are precisely what is disrupting the legacy Behavioral (workshop/subscription) franchise that still generates most revenue. The company is racing to monetize the same trend that is cannibalizing it — an unproven bet, not a moat.